Drug Label Change History
A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.
Pick a drug to see every version of its FDA prescribing information on DailyMed and what changed between any two, section by section, with the safety sections first. Or drop an SPL file to read it as a label.
- Source: DailyMed (NLM)
- Safety changes: FDA SrLC database
Examples: Xeljanz, Janumet, Ozempic, Wegovy, Rybelsus, Empaveli.
Recent safety-related label changes
157 label changes FDA approved from Aug 20, 2026 to Nov 12, 2026 that touched a boxed warning, contraindications, warnings, adverse reactions, interactions, specific populations or patient labeling.| What changed | |||
|---|---|---|---|
| Nov 12, 2026 | LazcluzeLazertinib mesylate | NDA219008 | FDA's summary |
| Nov 10, 2026 | GavretoPralsetinib | NDA213721 | FDA's summary |
| Nov 10, 2026 | MezofyAripiprazole | NDA211448 | FDA's summary |
| Nov 6, 2026 | HympavziMarstacimab-hncq | BLA761369 | FDA's summary |
| Nov 6, 2026 | WeliregBelzutifan | NDA215383 | FDA's summary |
| Nov 5, 2026 | AmjevitaAdalimumab-atto | BLA761024 | FDA's summary |
| Nov 4, 2026 | OrgovyxRelugolix | NDA214621 | FDA's summary |
| Nov 4, 2026 | ReleukoFilgrastim-ayow | BLA761082 | FDA's summary |
| Nov 4, 2026 | ZynlontaLoncastuximab tesirine-lpyl | BLA761196 | FDA's summary |
| Nov 3, 2026 | BomyntraDenosumab-bnht | BLA761398 | FDA's summary |
| Nov 3, 2026 | ConexxenceDenosumab-bnht | BLA761398 | FDA's summary |
| Nov 2, 2026 | ImpavidoMiltefosine | NDA204684 | FDA's summary |
| Oct 30, 2026 | CetraxalCiprofloxacin hydrochloride | NDA021918 | FDA's summary |
| Oct 30, 2026 | MinivelleEstradiol | NDA203752 | FDA's summary |
| Oct 30, 2026 | VivelleEstradiol | NDA020323 | FDA's summary |
| Oct 30, 2026 | Vivelle-DotEstradiol | NDA020538 | FDA's summary |
| Oct 29, 2026 | IlumyaTildrakizumab-asmn | BLA761067 | FDA's summary |
| Oct 28, 2026 | IfexIfosfamide | NDA019763 | FDA's summary |
| Oct 28, 2026 | PiqrayAlpelisib | NDA212526 | FDA's summary |
| Oct 26, 2026 | Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container | NDA019953 | FDA's summary |
| Oct 26, 2026 | Heparin Sodium 20,000 Units In Dextrose 5% In Plastic Container | NDA019952 | FDA's summary |
| Oct 26, 2026 | TalzennaTalazoparib tosylate | NDA211651 | FDA's summary |
| Oct 26, 2026 | TalzennaTalazoparib tosylate | NDA217439 | FDA's summary |
| Oct 23, 2026 | Awiqli FlextouchInsulin icodec | BLA761326 | FDA's summary |
| Oct 23, 2026 | JubbontiDenosumab-bbdz | BLA761362 | FDA's summary |
| Oct 23, 2026 | MonoferricFerric derisomaltose | NDA208171 | FDA's summary |
| Oct 23, 2026 | SkyriziRisankizumab-rzaa | BLA761105 | FDA's summary |
| Oct 23, 2026 | SkyriziRisankizumab-rzaa | BLA761262 | FDA's summary |
| Oct 22, 2026 | Vyleesi (Autoinjector)Bremelanotide acetate | NDA210557 | FDA's summary |
| Oct 21, 2026 | Levothyroxine SodiumLevothyroxine sodium | NDA202231 | FDA's summary |
| Oct 21, 2026 | ZyvoxLinezolid | NDA021130 | FDA's summary |
| Oct 21, 2026 | ZyvoxLinezolid | NDA021131 | FDA's summary |
| Oct 21, 2026 | ZyvoxLinezolid | NDA021132 | FDA's summary |
| Oct 20, 2026 | Dextrose 10% In Plastic Container | NDA019626 | FDA's summary |
| Oct 20, 2026 | Dextrose 2.5% In Plastic Container | NDA019626 | FDA's summary |
| Oct 20, 2026 | Dextrose 5% In Plastic Container | NDA019626 | FDA's summary |
| Oct 20, 2026 | Dextrose 7.7% In Plastic Container | NDA019626 | FDA's summary |
| Oct 20, 2026 | Dextrose 70% In Plastic Container | NDA019626 | FDA's summary |
| Oct 20, 2026 | ReblozylLuspatercept-aamt | BLA761136 | FDA's summary |
| Oct 16, 2026 | AyvakitAvapritinib | NDA212608 | FDA's summary |
| Oct 16, 2026 | Daybue StixTrofinetide | NDA219884 | FDA's summary |
| Oct 16, 2026 | ImkeldiImatinib mesylate | NDA219097 | FDA's summary |
| Oct 16, 2026 | KeytrudaPembrolizumab | BLA125514 | FDA's summary |
| Oct 16, 2026 | Keytruda QlexPembrolizumab;berahyaluronidase alfa-pmph | BLA761467 | FDA's summary |
| Oct 16, 2026 | OrladeyoBerotralstat hydrochloride | NDA214094 | FDA's summary |
| Oct 16, 2026 | PhyragoDasatinib | NDA216099 | FDA's summary |
| Oct 16, 2026 | SprycelDasatinib | NDA021986 | FDA's summary |
| Oct 15, 2026 | CosentyxSecukinumab | BLA125504 | FDA's summary |
| Oct 15, 2026 | CosentyxSecukinumab | BLA761349 | FDA's summary |
| Oct 15, 2026 | EnspryngSatralizumab | BLA761149 | FDA's summary |
| Oct 15, 2026 | MethotrexateMethotrexate | NDA214121 | FDA's summary |
| Oct 15, 2026 | Methotrexate LpfMethotrexate sodium | NDA011719 | FDA's summary |
| Oct 15, 2026 | Methotrexate Preservative FreeMethotrexate sodium | NDA011719 | FDA's summary |
| Oct 15, 2026 | Methotrexate Sodium Preservative FreeMethotrexate sodium | NDA011719 | FDA's summary |
| Oct 15, 2026 | SupraxCefixime | NDA202091 | FDA's summary |
| Oct 15, 2026 | ZilbrysqZilucoplan sodium | NDA216834 | FDA's summary |
| Oct 14, 2026 | AnktivaNogapendekin alfa inbakicept-pmln | BLA761336 | FDA's summary |
| Oct 14, 2026 | AprisoMesalamine | NDA022301 | FDA's summary |
| Oct 14, 2026 | AzulfidineSulfasalazine | NDA007073 | FDA's summary |
| Oct 14, 2026 | Azulfidine En-TabsSulfasalazine | NDA007073 | FDA's summary |
| Oct 14, 2026 | CanasaMesalamine | NDA021252 | FDA's summary |
| Oct 14, 2026 | DipentumOlsalazine sodium | NDA019715 | FDA's summary |
| Oct 14, 2026 | EnflonsiaClesrovimab-cfor | BLA761432 | FDA's summary |
| Oct 14, 2026 | LialdaMesalamine | NDA022000 | FDA's summary |
| Oct 14, 2026 | PentasaMesalamine | NDA020049 | FDA's summary |
| Oct 14, 2026 | RowasaMesalamine | NDA019618 | FDA's summary |
| Oct 13, 2026 | VelphoroSucroferric oxyhydroxide | NDA205109 | FDA's summary |
| Oct 9, 2026 | OlumiantBaricitinib | NDA207924 | FDA's summary |
| Oct 9, 2026 | RepathaEvolocumab | BLA125522 | FDA's summary |
| Oct 8, 2026 | TecentriqAtezolizumab | BLA761034 | FDA's summary |
| Oct 8, 2026 | Tecentriq HybrezaAtezolizumab and hyaluronidase-tqjs | BLA761347 | FDA's summary |
| Oct 7, 2026 | DuacBenzoyl peroxide; clindamycin phosphate | NDA050741 | FDA's summary |
| Oct 7, 2026 | TukysaTucatinib | NDA213411 | FDA's summary |
| Oct 6, 2026 | ProglycemDiazoxide | NDA017453 | FDA's summary |
| Oct 6, 2026 | RhapsidoRemibrutinib | NDA218436 | FDA's summary |
| Oct 6, 2026 | Sertraline HydrochlorideSertraline hydrochloride | NDA215133 | FDA's summary |
| Oct 5, 2026 | Acthar GelCorticotropin | NDA008372 | FDA's summary |
| Oct 5, 2026 | Cortrophin-ZincCorticotropin-zinc hydroxide | NDA009854 | FDA's summary |
| Oct 5, 2026 | Purified Cortrophin GelCorticotropin | NDA008975 | FDA's summary |
| Oct 2, 2026 | JaypircaPirtobrutinib | NDA216059 | FDA's summary |
| Oct 1, 2026 | RozlytrekEntrectinib | NDA212725 | FDA's summary |
| Oct 1, 2026 | RozlytrekEntrectinib | NDA218550 | FDA's summary |
| Sep 30, 2026 | CamzyosMavacamten | NDA214998 | FDA's summary |
| Sep 30, 2026 | MatulaneProcarbazine hydrochloride | NDA016785 | FDA's summary |
| Sep 30, 2026 | XenicalOrlistat | NDA020766 | FDA's summary |
| Sep 30, 2026 | ZepzelcaLurbinectedin | NDA213702 | FDA's summary |
| Sep 29, 2026 | AvtozmaTocilizumab-anoh | BLA761420 | FDA's summary |
| Sep 29, 2026 | AvtozmaTocilizumab-anoh | BLA761498 | FDA's summary |
| Sep 29, 2026 | DelstrigoDoravirine; lamivudine; tenofovir disoproxil fumarate | NDA210807 | FDA's summary |
| Sep 29, 2026 | EydenzeltAflibercept-boav | BLA761377 | FDA's summary |
| Sep 29, 2026 | PifeltroDoravirine | NDA210806 | FDA's summary |
| Sep 29, 2026 | PonlimsiDenosumab-adet | BLA761385 | FDA's summary |
| Sep 28, 2026 | RuxienceRituximab-pvvr | BLA761103 | FDA's summary |
| Sep 25, 2026 | Argatroban In Sodium ChlorideArgatroban | NDA022485 | FDA's summary |
| Sep 25, 2026 | GazyvaObinutuzumab | BLA125486 | FDA's summary |
| Sep 24, 2026 | LenvimaLenvatinib mesylate | NDA206947 | FDA's summary |
| Sep 24, 2026 | ValiumDiazepam | NDA013263 | FDA's summary |
| Sep 23, 2026 | CrestorRosuvastatin calcium | NDA021366 | FDA's summary |
| Sep 23, 2026 | PaxilParoxetine hydrochloride | NDA020031 | FDA's summary |
| Sep 23, 2026 | PaxilParoxetine hydrochloride | NDA020710 | FDA's summary |
| Sep 23, 2026 | Paxil CrParoxetine hydrochloride | NDA020936 | FDA's summary |
| Sep 23, 2026 | TepezzaTeprotumumab-trbw | BLA761143 | FDA's summary |
| Sep 22, 2026 | NubeqaDarolutamide | NDA212099 | FDA's summary |
| Sep 22, 2026 | PrexxartanValsartan | NDA209139 | FDA's summary |
| Sep 22, 2026 | ScemblixAsciminib hydrochloride | NDA215358 | FDA's summary |
| Sep 21, 2026 | WinrevairSotatercept-csrk | BLA761363 | FDA's summary |
| Sep 18, 2026 | AqneursaLevacetylleucine | NDA219132 | FDA's summary |
| Sep 18, 2026 | InluriyoImlunestrant tosylate | NDA218881 | FDA's summary |
| Sep 18, 2026 | SohonosPalovarotene | NDA215559 | FDA's summary |
| Sep 18, 2026 | VerzenioAbemaciclib | NDA208716 | FDA's summary |
| Sep 17, 2026 | SpravatoEsketamine | NDA211243 | FDA's summary |
| Sep 16, 2026 | KerendiaFinerenone | NDA215341 | FDA's summary |
| Sep 16, 2026 | XeljanzTofacitinib citrate | NDA203214 | FDA's summary |
| Sep 16, 2026 | XeljanzTofacitinib citrate | NDA213082 | FDA's summary |
| Sep 16, 2026 | Xeljanz XrTofacitinib citrate | NDA208246 | FDA's summary |
| Sep 16, 2026 | ZortressEverolimus | NDA021560 | FDA's summary |
| Sep 15, 2026 | JynarqueTolvaptan | NDA204441 | FDA's summary |
| Sep 14, 2026 | EvrysdiRisdiplam | NDA213535 | FDA's summary |
| Sep 14, 2026 | EvrysdiRisdiplam | NDA219285 | FDA's summary |
| Sep 14, 2026 | TagrissoOsimertinib mesylate | NDA208065 | FDA's summary |
| Sep 11, 2026 | ImdelltraTarlatamab-dlle | BLA761344 | FDA's summary |
| Sep 11, 2026 | JoenjaLeniolisib phosphate | NDA217759 | FDA's summary |
| Sep 11, 2026 | KybellaDeoxycholic acid | NDA206333 | FDA's summary |
| Sep 9, 2026 | AmeluzAminolevulinic acid hydrochloride | NDA208081 | FDA's summary |
| Sep 2, 2026 | Etopophos Preservative FreeEtoposide phosphate | NDA020457 | FDA's summary |
| Sep 2, 2026 | FyarroSirolimus | NDA213312 | FDA's summary |
| Sep 2, 2026 | ThalomidThalidomide | NDA020785 | FDA's summary |
| Sep 1, 2026 | Cleocin HydrochlorideClindamycin hydrochloride | NDA050162 | FDA's summary |
| Aug 31, 2026 | Bactocill In Plastic ContainerOxacillin sodium | NDA050640 | FDA's summary |
| Aug 31, 2026 | BavencioAvelumab | BLA761049 | FDA's summary |
| Aug 31, 2026 | Cefazolin In DextroseCefazolin sodium | NDA207131 | FDA's summary |
| Aug 31, 2026 | ImfinziDurvalumab | BLA761069 | FDA's summary |
| Aug 31, 2026 | ImjudoTremelimumab-actl | BLA761289 | FDA's summary |
| Aug 31, 2026 | LibtayoCemiplimab-rwlc | BLA761097 | FDA's summary |
| Aug 31, 2026 | LoqtorziToripalimab-tpzi | BLA761240 | FDA's summary |
| Aug 31, 2026 | Penpulimab-KcqxPenpulimab-kcqx | BLA761258 | FDA's summary |
| Aug 31, 2026 | UnloxcytCosibelimab-ipdl | BLA761297 | FDA's summary |
| Aug 31, 2026 | YervoyIpilimumab | BLA125377 | FDA's summary |
| Aug 28, 2026 | BesremiRopeginterferon ALFA-2B-NJFT | BLA761166 | FDA's summary |
| Aug 28, 2026 | StelaraUstekinumab | BLA125261 | FDA's summary |
| Aug 28, 2026 | StelaraUstekinumab | BLA761044 | FDA's summary |
| Aug 28, 2026 | YusimryAdalimumab-aqvh | BLA761216 | FDA's summary |
| Aug 27, 2026 | MounjaroTirzepatide | NDA215866 | FDA's summary |
| Aug 27, 2026 | SunlencaLenacapavir sodium | NDA215973 | FDA's summary |
| Aug 27, 2026 | SunlencaLenacapavir sodium | NDA215974 | FDA's summary |
| Aug 25, 2026 | TevimbraTislelizumab-jsgr | BLA761232 | FDA's summary |
| Aug 25, 2026 | TivicayDolutegravir sodium | NDA204790 | FDA's summary |
| Aug 25, 2026 | Tivicay PdDolutegravir sodium | NDA213983 | FDA's summary |
| Aug 25, 2026 | ZiiheraZanidatamab-hrii | BLA761416 | FDA's summary |
| Aug 24, 2026 | ImaavyNipocalimab-aahu | BLA761430 | FDA's summary |
| Aug 21, 2026 | BenlystaBelimumab | BLA125370 | FDA's summary |
| Aug 21, 2026 | BenlystaBelimumab | BLA761043 | FDA's summary |
| Aug 20, 2026 | CotellicCobimetinib fumarate | NDA206192 | FDA's summary |
| Aug 20, 2026 | EmpaveliPegcetacoplan | NDA215014 | FDA's summary |
| Aug 20, 2026 | OgsiveoNirogacestat hydrobromide | NDA217677 | FDA's summary |
| Aug 20, 2026 | TakhzyroLandelumab-flyo | BLA761090 | FDA's summary |
| Aug 20, 2026 | ZelborafVemurafenib | NDA202429 | FDA's summary |
Read an SPL file
Open an SPL label file
Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.
Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine
About label change history
How to read a comparison
Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.
The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.
Which label is shown
A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.
Frequently asked questions
- Where do the versions come from?
- DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
- Is a new version a new FDA approval?
- Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
- Why does the published date differ from the label's revised date?
- The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
- How is the comparison made?
- Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
- Is my SPL file uploaded?
- No. A file you drop on this page is read in your browser tab and never sent to Arca.